Prexton CEO On Future For Novel Parkinson's Therapy

François Conquet, CEO of Prexton Therapeutics, a biotech focused on central nervous system disorders, discusses the company's founding as a spinoff from German Merck and its mGluR4 receptor technology, which he says has piqued the interest of big pharma.